ARIA/HGSI- Could be us in the not too distant future(although I think they needed this a lot more than us): Monday 6:13 PM GlaxoSmithKline (GSK) may bid $25/share for Human Genome Sciences (HGSI), the Daily Mail speculates, citing their partnership in developing the FDA-approved lupus drug Benlysta. With Merck (MRK) and Biogen (BIIB) also sniffing around the company, GSK "could decide now would be an opportune time to make a move on HGS." HGSI +4.9% AH. Seeking Alpha(Market Currents)